Michael Morrissey, President and CEO of Exelixis (EXEL), has demonstrated a clear selling bias in his insider transactions, with $37.5 million in total sales outweighing $10.5 million in purchases across 23 filings. His activity has been exclusively concentrated in EXEL shares, with no recent trades reported since February 2026. The most significant transactions occurred in early 2026, including a $16.2 million sale on February 13 and a $5.3 million sale two days later, both coded as derivative dispositions (Code F). These followed a $10.5 million acquisition (Code M) on the same February 13 date, suggesting a simultaneous exercise and sale of equity awards. Earlier transactions show a pattern of periodic dispositions, including a $6.3 million sale in January 2026 and multiple smaller sales throughout 2024-2025, typically following option exercises or award vesting events. The absence of open market purchases outside of equity award transactions indicates Morrissey's activity has been primarily driven by the monetization of compensation-related holdings rather than discretionary buying. The zero-dollar transactions reflect administrative filings for gifts or other non-sale transfers. This pattern is consistent with executives systematically liquidating equity compensation, though the concentration of large sales in early 2026 represents an acceleration in monetization compared to prior years.
AI-assisted summary